Xanadu Bio is a privately held, next generation nanoparticle delivery company focusing on the delivery of mRNA and other nucleic acids that utilizes PACE platform technology. PACE technology is a next-generation polymeric nanoparticle that consists of three monomers that are fully biodegradable, and allows for efficient delivery of and protection from nuclease degradation for different types of nucleic acids, including mRNA. PACE is easily manufactured, cost effective, scalable and can be functionalized to allow both organ and cell specific delivery of its nucleic acid payload. PACE is formulated and optimized to allow safe delivery either systemically or intranasally. Leveraging PACE, Xanadu is initially focused on developing nasal vaccine boosters for the prevention and treatment of SARS CoV-2 infection and for other indications.
Company Details
- Employees
- 7
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://xanadubio.com/
Xanadu Bio Questions
Xanadu Bio's website is http://xanadubio.com/
Xanadu Bio's LinkedIn profile is https://www.linkedin.com/company/xanadu-bio
Xanadu Bio has
7 employees.
View email and phone details for 7
employees at Xanadu Bio.
Xanadu Bio's industry is
Biotechnology Research
Xanadu Bio's top competitors are
Rigimmune Inc.,
Panv, Inc.,
Genentech,
Immunome, Inc.,
Popvax,
Talos Surgical,
Celestial Therapeutics,
Gennao Bio,
Flashpoint Therapeutics,
Morphimmune.
Xanadu Bio's categories are Biotechnology Research
